# NanoViricides, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/NanoViricides, Inc). ## Overview NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing nanomedicine-based antiviral drugs using its licensed TheraCour platform. The company is focused on creating broad-spectrum therapies for multiple viral diseases, with its first candidate, NV-387, having completed Phase Ia/Ib safety and tolerability testing and moving toward Phase II efficacy trials. ## Products & services • NV-387 broad-spectrum antiviral drug candidate • Nanoviricides™ platform-based antiviral programs • Preclinical and IND-enabling drug development • Clinical-stage antiviral formulation and manufacturing • Licensing and co-development of antiviral technologies - **Clinical-stage antiviral drug candidates** (0%) — Drug programs such as NV-387 that are being advanced through preclinical and clinical development for viral diseases. - **Nanoviricides platform technology** (0%) — Licensed nanomedicine technology used to design antiviral candidates against multiple virus families. - **Drug formulation and cGMP manufacturing** (0%) — In-house and subcontracted capabilities for formulation, filling, finishing, and clinical trial supply. - **Research and development services** (0%) — Internal and outsourced preclinical, virology, toxicology, and regulatory development work. - **Licensing and partnering** (0%) — Potential out-licensing, co-development, and partnership arrangements for antiviral programs. - NV-387 broad-spectrum antiviral candidate - Nanoviricides™ antiviral drug platform - Preclinical and IND-enabling development programs - Clinical trial material manufacturing and formulation - Technology licensing and co-development opportunities ## Customers NanoViricides does not currently have commercial customers or product revenue; its near-term counterparties are regulators, CROs, CMOs, and potential pharmaceutical partners. If programs succeed, the eventual buyers would be healthcare systems, physicians, and distributors purchasing approved antiviral drugs for specific viral indications. The company also seeks non-dilutive funding and licensing partners to support development before commercialization. - **Regulatory and clinical development ecosystem** (primary) — FDA-facing development work, clinical trial execution, and regulatory submissions needed to advance candidates toward approval. - **Contract research organizations** (primary) — External labs and CROs perform animal studies, virology testing, toxicology, biostatistics, and trial support. - **Contract manufacturing organizations** (secondary) — CMOs may manufacture injectable clinical trial material when in-house capacity is not used. - **Pharmaceutical licensing partners** (secondary) — Potential partners may fund, co-develop, or license antiviral programs for upfronts, milestones, and royalties. - **Future healthcare purchasers** (emerging) — Hospitals, physicians, and distributors would buy approved antiviral products if commercialization succeeds. - No commercial customers yet; company has no product revenue to date - Regulators and clinical trial partners support development and approvals - CROs and CMOs buy outsourced research, testing, and manufacturing work - Pharma partners may license or co-develop antiviral programs - Future end buyers would be hospitals, physicians, and distributors ## Geography NanoViricides is headquartered in Shelton, Connecticut and operates as a U.S.-based development-stage company. Its licenses are described as worldwide, and management has stated it intends to pursue co-development and licensing agreements in the U.S. and internationally. Because the company has no product revenue, geography currently matters more for R&D operations, regulatory pathways, and future partnering than for sales mix. - Headquartered and operating in Shelton, Connecticut, United States - U.S. location supports lab work, cGMP capability, and regulatory filings - Worldwide license rights expand potential future commercialization scope - International partnering is part of the licensing strategy - No disclosed country revenue mix because the company has no revenue ## Strategy The company’s strategy is to advance a platform of antiviral nanomedicines from discovery through cGMP manufacturing and clinical trials using as much in-house capability as possible. It aims to reduce development risk and cost by controlling formulation, characterization, and some manufacturing steps, while using CROs and external partners where needed. Management also intends to pursue licensing and co-development deals to obtain non-dilutive funding and broaden commercialization options. - **Advance NV-387 through clinical development** (short-term) — The first candidate is the lead asset and the main path to proof of concept and eventual approval. - **Expand platform into multiple viral indications** (medium-term) — A broader pipeline can reuse the same technology and improve the chance of a commercial outcome. - **Strengthen in-house manufacturing and QC** (medium-term) — Internal cGMP capability can lower costs, improve control, and reduce dependence on third parties. - **Secure partnerships and non-dilutive capital** (short-term) — The company has no revenue and needs external funding to support long development timelines. - Advance NV-387 toward Phase II and additional indications - Use the nanoviricides platform across multiple viral diseases - Keep key formulation, QC, and manufacturing capabilities in-house - Use CROs/CMOs selectively to speed development and manage cost - Pursue licensing and co-development for non-dilutive funding ## Risks NanoViricides is a development-stage company with no approved products, no revenue, and a continuing need for capital, so execution risk is high. Its business depends on successful preclinical and clinical results, regulatory approvals, and the ability to manufacture complex nanomedicines reliably at cGMP standards. Competition from larger antiviral developers, as well as the possibility that vaccines or alternative therapies reduce market size, also creates meaningful commercialization risk. - **No commercial products or revenue** [critical] — The company is still in development and has not generated product sales, so it depends on future approvals and funding. - **Clinical development failure** [high] — Lead candidates must prove safety and efficacy in humans before any commercialization can occur. - **Capital raising and dilution** [high] — Management states substantial additional capital will be needed to fund operations and trials. - **Manufacturing and cGMP execution** [high] — Complex nanomedicine production under cGMP conditions is a known industry failure point. - **Competitive and market substitution risk** [medium] — Existing antivirals, vaccines, or superior therapies could reduce demand for the company’s candidates. - No approved products or revenue, so survival depends on development success - Clinical and regulatory failure could delay or prevent commercialization - Raising additional capital is likely necessary and may be dilutive - Complex nanomedicine manufacturing can fail or become costly - Large competitors and vaccines may limit future market opportunity ## Accounting The most important accounting issue is that research and development costs are expensed as incurred, so reported losses closely track development activity rather than commercial performance. Because the company has no revenue, investors should focus on how R&D, external CRO/CMO spending, and capitalized versus expensed facility-related items affect the income statement and cash burn. Long-lived assets, including its Shelton campus and equipment, also create depreciation and potential impairment considerations if development plans change. - **Research and development expense recognition** — Main driver of operating loss - **Long-lived asset depreciation and impairment** — Could affect operating expense and asset values - **Potential licensing revenue recognition** — Could materially affect future revenue pattern - **Capitalization versus expense of development-related spending** — Affects loss recognition timing - R&D is expensed as incurred, driving reported losses during development - External CRO and CMO costs flow through expense as work is performed - No revenue means operating results are dominated by development spending - Owned campus and equipment create depreciation and impairment considerations - Future licensing deals could introduce milestone and royalty recognition issues --- *Last updated: 2026-09-24T11:45:55.190641+00:00*